
BONESUPPORT Q4 - Operating leverage set to accelerate

Redeye returns with more flesh on the bone regarding the Q4 report. While strong Fx tailwinds boosted the EBIT beat, we overlook our OPEX assumptions and update our WACC to 8% (9%). We raise our fair value range.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[BONESUPPORT Q4 - Operating leverage set to accelerate](#)